jRCT2031230332进行中（未招募）不适用
An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 25
- 主要终点
- Confirmed OR according to RECIST 1.1 as assessed by Investigator
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Are diagnosed with nsqNSCLC histologically or cytologically confirmed
- •Radiologically confirmed/documented disease progression during or after the following systemic therapies
- •Measurable disease per RECIST v1.1, as assessed by the Investigator
- •ECOG PS 0 or 1
- •Adequate hematologic function
- •Adequate hepatic function
- •Adequate renal function
- •Archival FFPE tumor tissue is required
- •Phase 2a part only: central liquid biopsy analysis of tumor molecular alterations with an assay with appropriate regulatory status. Participants will be allocated to 1 of the strata as follows:
- •STK11 and/or KEAP1 loss of function mutation: Stratum A
- •ATM, ARID1A, SMARCA4, or PBRM1 loss of function mutation: Stratum B
- •Other or nonidentified alterations: Stratum C
- •Other protocol defined inclusion criteria could apply
排除标准
- •Participants with tumors harboring actionable EGFR or ALK genomic aberrations as determined by local assessment with assays of appropriate regulatory status
- •History of additional malignancy within 3 years before the date of enrollment
- •Known brain metastase
- •Active and/or uncontrolled infection
- •Organ transplantation, including allogeneic stem cell transplant
- •Uncontrolled or poorly controlled arterial hypertension, symptomatic congestive heart failure (New York Heart Association Classification >= Class III), uncontrolled cardiac arrhythmia, calculated QTc average using the QTcF > 470 msec; unstable angina pectoris, myocardial infarction or a coronary revascularization procedure, cerebral vascular accident, transient ischemic attack, or any other significant vascular disease within 180 days of study intervention start
- •History of (noninfectious) pneumonitis that required systemic corticosteroids or current pneumonitis/interstitial lung disease
- •Any other clinical condition, uncontrolled concurrent illness, or other situations, which in the Investigator's opinion would not make the patient a good candidate for the study or may potentially impact the absorption of M1774 such as (but not limited to) significant small bowel resection, gastric surgery, or exocrine pancreatic insufficiency requiring pancreatic enzyme replacement therapy
- •Prior use of ATR, CHK1, and WEE1 inhibitors
- •Prohibited concomitant therapy
- •Live vaccines within 4 weeks of first dose of study intervention and while receiving study intervention
- •Active or history of autoimmune disease that has required chronic systemic immunosuppressive therapy (including but not limited to corticosteroids [e.g. prednisone > 10 mg/day] or equivalent), that might deteriorate when receiving immunostimulatory agent, or history of irAE Grade >= 3 or any toxicity that led to permanent discontinuation of prior anti-PD-1/PD-L1 therapy.
- •Participants who received prior chemotherapy, biological therapy (e.g. antibodies) or systemic immunostimulatory agents (e.g. interferon and interleukin 2) within 4 weeks (6 weeks for nitrosurea, mitomycin-C), or who have been treated with small molecule therapeutics or any investigational agents within 4 weeks prior to starting study interventions, or within 5 half-lives, whichever is shorter
- •Prior radiotherapy within 14 days before the first dose of study intervention or prior lung radiotherapy of > 30 Gy within 12 weeks before the first dose of study intervention
- •Persistence of AEs related to any prior treatments that have not recovered to Grade <= 1
- •Other protocol defined exclusion criteria could apply.
结局指标
主要结局
Confirmed OR according to RECIST 1.1 as assessed by Investigator
时间窗: Phase 2a
Confirmed OR according to RECIST 1.1 as assessed by Investigator
Occurrence of AEs and treatment-related AEs
时间窗: Phase 1b
Occurrence of AEs and treatment-related AEs
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
2 期
A trial for men with advanced penile cancer to see if immunotherapy is an effective treatment either given on its own or at the same time as chemotherapyCancerISRCTN95561634niversity Hospitals Bristol NHS Foundation Trust47
进行中（未招募）
1 期
A phase II trial of belimumab in combination withrituximab/venetoclax in patients with refractory orrelapsed chronic lymphocytic leukemiaRefractory or relapsed chronic lymphocytic leukemiaMedDRA version: 21.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002622-87-DEniversity Hospital Tuebingen120
招募中
1 期
A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemiarefractory or relapsed chronic lymphocytic leukemiaMedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2024-511474-68-00niversitaetsklinikum Tuebingen AöR120
进行中（未招募）
2 期
A trial of 3-weekly cemiplimab in patients with locally advanced basal cell carcinomaCancerISRCTN10511385niversity Hospitals Bristol and Weston NHS Foundation Trust41
进行中（未招募）
1 期
Cemiplimab treatment in patients with locally advanced or metastatic blood vessel cancer (angiosarcoma)EUCTR2020-005465-13-NLRadboudumc18